Virologic Response and Safety of Ibuzatrelvir, A Novel SARS-CoV-2 Antiviral, in Adults With COVID-19
2024 · Clinical Infectious Diseases · 10 citations
https://doi.org/10.1093/cid/ciae529
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
29
Papers
224
Citations
9
h-index
9
i10-index
Mahta Mortezavi is an academic researcher from Pfizer (United States). The author has contributed to research in topics: Rheumatoid Arthritis Research and Therapies & Autoimmune and Inflammatory Disorders Research & SARS-CoV-2 and COVID-19 Research. The author has an h-index of 9, co-authored 25 publications.
ORCID: 0000-0003-4666-071XClick to start Chat